{"id":19638,"date":"2020-12-10T18:57:27","date_gmt":"2020-12-10T18:57:27","guid":{"rendered":"https:\/\/dejalex.com\/it\/2020\/12\/accordi-pay-for-delay-e-medicinali-generici-la-commissione-sanziona-teva-e-cephalon\/"},"modified":"2020-12-14T21:43:50","modified_gmt":"2020-12-14T21:43:50","slug":"accordi-pay-for-delay-e-medicinali-generici-la-commissione-sanziona-teva-e-cephalon","status":"publish","type":"post","link":"https:\/\/www.dejalex.com\/it\/2020\/12\/accordi-pay-for-delay-e-medicinali-generici-la-commissione-sanziona-teva-e-cephalon\/","title":{"rendered":"ACCORDI PAY-FOR-DELAY E MEDICINALI GENERICI. LA COMMISSIONE SANZIONA TEVA E CEPHALON"},"content":{"rendered":"<p>In data 26 novembre 2020, la Commissione Europea ha sanzionato le societ\u00e0 farmaceutiche Teva Pharmaceutical Industries Ltd. (&#8220;Teva&#8221;) e Cephalon Inc. (&#8220;Cephalon&#8221;) per avere stipulato un accordo c.d. \u201cpay-for-delay\u201d  allo scopo di ritardare l&#8217;ingresso sul mercato di una versione generica pi\u00f9 economica del farmaco modafinil della Cephalon dopo la scadenza dei relativi brevetti principali&#8230;<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-2114 aligncenter\" src=\"https:\/\/dejalex.com\/it\/wp-content\/uploads\/2020\/12\/Articolo_Accordi-pay-for-delay-e-medicinali-generici.-La-Commissione-sanziona-Teva-e-Cephalon.jpg\" alt=\"\" width=\"557\" height=\"789\" \/><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/dejalex.com\/it\/wp-content\/uploads\/2020\/12\/Articolo_Accordi-pay-for-delay-e-medicinali-generici.-La-Commissione-sanziona-Teva-e-Cephalon.pdf\" target=\"_blank\" rel=\"noopener\"><i  class=\"x-icon x-icon-download\" data-x-icon-s=\"&#xf019;\" aria-hidden=\"true\"><\/i> Scarica l&#8217;articolo<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[x_icon type=\"tag\"] Diritto Europeo e della Concorrenza, Farmaceutico e Life Sciences, Prospettive<\/p>\n","protected":false},"author":3,"featured_media":17673,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[338,370,402,422,307],"tags":[],"class_list":["post-19638","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-diritto-europeo-e-della-concorrenza","category-farmaceutico-e-life-sciences","category-prospettive","category-pubblicazioni","category-roberto-jacchia-it"],"_links":{"self":[{"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/posts\/19638","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/comments?post=19638"}],"version-history":[{"count":2,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/posts\/19638\/revisions"}],"predecessor-version":[{"id":19640,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/posts\/19638\/revisions\/19640"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/media\/17673"}],"wp:attachment":[{"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/media?parent=19638"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/categories?post=19638"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/tags?post=19638"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}